bc, page-7

mik, think u might be thinking too much here?


in the diagnostic world, it is always about getting to increase the sensitivity and specificity of an antigen or an antibody.

if mixngo can achieve this, companies will definitely be keen on making that switch. there are so many many diseases that current dx kits are not able to diagnose at a high enough sensitivity.

if by incorporating mixngo into the kits can help to raise that, companies will definitely make that switch.


anteo has been mentioning about how mixngo has helped to achieve test results of molecular levels, the companies are testing them. the market is unsure if this could be true. but once an ivd signs up, major re rating is bound to happen.


meanwhile patience is key. euro patent approval ann will be pleasing as it helps with the IP of anteo's key asset.